Acurx price target raised to $14 from $13 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Acurx Pharmaceuticals to $14 from $13 and keeps a Buy rating on the shares. The company announced that all 15 ibezapolstat-treated patients in the Phase 2b study who achieved clinical cure at end of treatment remained free of C. difficile infection recurrence through one month after treatment, which is impressive, As previously reported,